These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26098709)

  • 1. Spindle Cell Atypical Fibroxanthoma: Myofibroblastic Differentiation Represents a Diagnostic Pitfall in This Variant of AFX.
    Harding-Jackson N; Sangueza M; Mackinnon A; Suster S; Plaza JA
    Am J Dermatopathol; 2015 Jul; 37(7):509-14; quiz 515-6. PubMed ID: 26098709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma.
    Sakamoto A; Oda Y; Yamamoto H; Oshiro Y; Miyajima K; Itakura E; Tamiya S; Honda Y; Ishihara A; Iwamoto Y; Tsuneyoshi M
    Virchows Arch; 2002 Apr; 440(4):404-9. PubMed ID: 11956822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of CD10, wide-spectrum keratin, p63, and podoplanin in the distinction of epithelioid and spindle cell tumors of the skin: an immunohistochemical study of 81 cases.
    Buonaccorsi JN; Plaza JA
    Am J Dermatopathol; 2012 Jun; 34(4):404-11. PubMed ID: 22257901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clear cell atypical fibroxanthoma:a clinicopathologic study.
    Crowson AN; Carlson-Sweet K; Macinnis C; Taylor JR; Battaglia T; LaMar WL; Minor D; Sutter S; Hill T
    J Cutan Pathol; 2002 Jul; 29(6):374-81. PubMed ID: 12135470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.
    de Feraudy S; Mar N; McCalmont TH
    Am J Surg Pathol; 2008 Aug; 32(8):1111-22. PubMed ID: 18545147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical distinction of cutaneous spindle cell carcinoma.
    Morgan MB; Purohit C; Anglin TR
    Am J Dermatopathol; 2008 Jun; 30(3):228-32. PubMed ID: 18496422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pleomorphic and dedifferentiated leiomyosarcoma: a clinicopathologic analysis].
    Sun M; Liu JG; Weng QY; Yu L; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2018 Feb; 47(2):87-93. PubMed ID: 29429158
    [No Abstract]   [Full Text] [Related]  

  • 8. [Myxoid variant of angiomatoid fibrous histiocytoma: a clinicopathologic analysis of 3 cases].
    Gong QX; Zhang ZH; Fan QH
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):700-705. PubMed ID: 30220125
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue.
    Perez-Montiel MD; Plaza JA; Dominguez-Malagon H; Suster S
    Am J Dermatopathol; 2006 Apr; 28(2):105-11. PubMed ID: 16625070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome.
    Hanlon A; Stasko T; Christiansen D; Cyrus N; Galan A
    Dermatol Surg; 2017 Mar; 43(3):431-436. PubMed ID: 28079637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign fibrous histiocytoma (dermatofibroma) of the face: clinicopathologic and immunohistochemical study of 34 cases associated with an aggressive clinical course.
    Mentzel T; Kutzner H; Rütten A; Hügel H
    Am J Dermatopathol; 2001 Oct; 23(5):419-26. PubMed ID: 11801774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of low-affinity nerve growth factor receptor (P 75) immunostaining in atypical fibroxanthoma.
    Bull C; Mirzabeigi M; Laskin W; Dubina M; Traczyc T; Guitart J; Gerami P
    J Cutan Pathol; 2011 Aug; 38(8):631-5. PubMed ID: 21623867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keloidal atypical fibroxanthoma: a case series.
    Kim J; McNiff JM
    J Cutan Pathol; 2009 May; 36(5):535-9. PubMed ID: 19476521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic atypical fibroxanthoma.
    Satter EK
    Dermatol Online J; 2012 Sep; 18(9):3. PubMed ID: 23031370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical Characteristics of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: A Systematic Review and Meta-Analysis.
    Ørholt M; Abebe K; Aaberg F; Rasmussen LE; Daugaard S; Loya AC; Herly M; Vester-Glowinski PV
    Am J Dermatopathol; 2022 Dec; 44(12):913-920. PubMed ID: 36395448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase of atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective analysis of four German skin cancer centers.
    Kuntz T; Siebdrath J; Hofmann SC; Baltaci M; Schaller J; Hellmich M; von Goltzheim LS; Assaf C; Oellig F; Michalowitz AL; Helbig D; Kreuter A
    J Dtsch Dermatol Ges; 2022 Dec; 20(12):1581-1588. PubMed ID: 36442137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma.
    Kanner WA; Brill LB; Patterson JW; Wick MR
    J Cutan Pathol; 2010 Jul; 37(7):744-50. PubMed ID: 20184665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker.
    Hartel PH; Jackson J; Ducatman BS; Zhang P
    J Cutan Pathol; 2006 Sep; 33 Suppl 2():24-8. PubMed ID: 16972949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The many faces of Atypical fibroxanthoma.
    Agaimy A
    Semin Diagn Pathol; 2023 Jul; 40(4):306-312. PubMed ID: 37438163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleomorphic spindle cell dermal neoplasm with dot-like keratin reactivity: keratin-positive AFX or carcinoma?
    Ellis R; Chase E; Barland A; Rajpara A; Fraga GR
    J Cutan Pathol; 2015 Nov; 42(11):847-52. PubMed ID: 26041010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.